INTRODUCTION
Famotidine is a histamine H 2 -receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Johnson & Johnson/Merck under the trade names Pepcidine and Pepcid and by Astellas under the trade name Gaster. Unlike cimetidine, the first H 2 antagonist, famotidine has no effect on the cytochrome P450 enzyme system, and does not appear to interact with other drugs. 1 Oral drug administration has been the predominant route for drug delivery. During the past two decades, numerous oral delivery systems have been developed to act as drug reservoirs from which the active substance can be released over a defined period of time at a predetermined and controlled rate. The reasons for this are essentially physiological and usually affected by the GI transit of the form, especially its gastric residence time (GRT), which appears to be one of the major causes of the overall transit time variability. 2 Gastroretentive floating microspheres are low-density systems that have sufficient buoyancy to float over gastric contents and remain in stomach for prolonged periods. As the system floats over gastric contents, the drug is released slowly at a desired rate resulting in increased gastric retention with reduced fluctuations in the plasma drug concentration. When microspheres come in contact with gastric fluid, the gel formers, polysaccharides, and polymers hydrate to form a colloidal gel barrier that controls the rate of fluid penetration into the device and consequent drug release. As the exterior surface of the dosage form dissolves, the gel layer is maintained by the hydration of the adjacent hydrocolloid layer. The air trapped by the swollen polymer lowers the density and confers buoyancy to the microspheres. However, a minimal gastric content is needed to allow proper achievement of buoyancy [3] [4] [5] [6] [7] [8] .
PREFORMULATION STUDIES
Preformulation testing is an investigation of physical and chemical properties of drug substance alone and when combined with excipients. It is the first step in the rational development of dosage form.
ANALYSIS OF FAMOTIDINE

Indentification of drug by IR Spectra
The IR spectrum of famotidine in KBr dispersion was analysed using ABB Bomen model MB 104 Fourier Transform Infrared Spectrophotometer. From the IR spectrum obtained interpretations were made and compared with that of standard.
ABSTRACT
The main aim of this study is to develop a gastro retentive multiple unit floating drug delivery system for a drug which is poorly absorbed from lower gastrointestinal tract of famotidine. The hollow micro spheres were prepared by the emulsion solvent diffusion technique using eudragit RS 100 as a release rate controlling polymer in the ratios 1:1, 1:2 ,1:3,and 1:4.The prepared microspheres were evaluated for drug-polymer compatibility, micromeritic properties, drug entrapment efficiency, invitro buoyancy and drug release studies. The mean particle size increased with increase in the polymer concentration. The micromeritic properties were found to be improved when compared to pure drug .Scanning electron microscopy confirmed the hollow structure with smooth external surface. The drug and polymer were found to be compatible as seen in IR studies. The entrapment efficiency of formulation E1-E4 were 70.42%, 70.12%, 69.22% and 67.78% and for the formulation C1-C4 were 72.19%, 68.67%, 67.14% and 66.87%, cellulose acetate containing microspheres showed a desirable high drug content and entrapment efficiency respectively. The microspheres floated up to 10 h over the surface of the gastric buffer medium and the buoyancy percentage was found to be in the range of 60-39% of E1-E4and C1-C4. In-vitro drug release studies showed that the prepared microspheres exhibited prolonged drug release for more than 12 hours. The mechanism of drug release wasfound to be a combination of both peppas and zero order release kinetics. The developed floating microspheres of aceclofenac may be used for prolonged drug release for at least 12 h for maximizing the therapeutic efficacy along with patient compliance. Keywords: Famotidine, Ethyl acetate, acetone, Eudragit RL100, Higuchi's model, PVA, scanning electron microscopy. Microspheres were prepared by emulsion solvent diffusion method 9 . Four different ratios (E1-E4) of floating hollow microspheres of famotidine were prepared by using Eudragit RL 100 as polymer calculated quantity (as mentioned in table 4) of Eudragit RL 100 and Glyceryl monostearate were dissolved in 20 ml of mixture of ethanol and dichloromethane (1:1) to get a homogenous polymer solution. Famotidine was dispersed uniformly in the polymer solution and then it was poured slowly in to 200 ml of 0.75% w/v polyvinyl alcohol in distilled water. The emulsion formed was stirred continuously for 2 hours using propeller type agitator at 1500 rpm. The temperature was maintained at 40 o C. The finely dispersed droplets of the polymer solution of drug were solidified in the aqueous phase via diffusion of the solvent, leaving the cavity of microspheres filled with water. Hollow microspheres formed were filtered using nylon cloth and washed repeatedly with distilled water. 
Preparation of famotidine floating hollow microspehers using cellulose acetate
Four different ratio of (C1 (1:1), C2 (1:2), C3 (1:3), C4
(1:4) ) famotidine floating hollow microspheres were prepared using cellulose acetate were prepared by same procedure as that of Eudragit RL 100. The solvent system used was acetone: ethyl acetate in the ratio of 1:1. Calculated quantities for four different ratios are mentioned in table 2 
Entrapment efficiency
To determine the entrapment efficiency 50 mg of microspheres was taken in a 50 ml standard flask, 10 ml of methanol was added to solubilize and made up to the volume with distilled water. The drug content was determined by measuring the absorbance at 265 nm using Shimadzu UV 1601 spectrophotometer.
The percentage drug entrapment efficiency of microspheres were calculated by using the formula Amount of drug actually present
Theoretical drug load expected
The results are shown in table 4
Buoyancy percentage
Floating behavior of hollow microspheres was studied in a USP XXIV dissolution apparatus (Type II) by spreading the microspheres (300 mg) on a 0.1mol L -1 HCl containing 0.02% between 80 as a surfactant. The medium was agitated with a paddle rotating at 100 rpm and maintained at 37°C. After 12 hrs, both the floating and the settled portions of microspheres were collected separately. The microspheres were dried and weighed. Buoyancy percentage was calculated using the formula.
Weight of buoyant microspheres % buoyancy of microspheres
Initial weight of buoyant microspheres
The results are shown in Table 5 .
In vitro drug release study
The release rate of famotidine from microspheres was determined using USP dissolution testing apparatus I (Basket type). The dissolution test was performed using 900 ml of 0.1N HCl, at 37 ± 0.5°C at100 rpm 10 . Withdrawn samples (5 ml) were analyzed spectrophotometrically at 265 nm. The volume was replenished with the same amount of fresh dissolution fluid each time to maintain the sink condition. All experiments were performed in triplicate. Linear regression was used to analyze the in vitro release mechanism.
Mechanism of drug release
The in vitro data was treated according to Zero order, First order, Higuchi, Korsmeyer Peppas and Hixson-Crowell equation and the coefficient of correlation was determined. The results are given in Table-7 Microspheres of selected formulations E1-A and C1-A were prepared based on the prototype formulation (E1 and C1) to assess the reproducibility. The method of preparations of E1-A and C1-A were same as that of E1 and C1 respectively. 
Characterization of the Selected Formulations (E1-A and C1-A)
Characteristics of microspheres such as particle size, drug content, entrapment efficiency, percentage buoyancy and in vitro release were evaluated.
MORPHOLOGY: Size and Shape
The external and internal morphology of the microspheres were studied by scanning electron microscopy (SEM). The samples for SEM were prepared by lightly sprinkling on a double adhesive tape stuck to an aluminum stub. The stubs were then coated with platinum to a thickness of about 10 Å under an argon atmosphere using a gold sputter module in a high-vacuum evaporator. Afterwards, the stubs containing the coated samples were placed in the scanning electron microscope (JSM-6360A, JEOL, Tokyo, Japan) chamber. The samples were then randomly scanned and photomicrographs were taken at the acceleration voltage of 15 kV to investigate the internal morphology, hollow microspheres were cut with a knife. The SEM photomicrographs of formulations E1-A and C1-A are shown in fig 3. (a) (b) 70.95% (C1-A) respectively. The percentage cumulative drug release of E1-A and C1-A at the end of 10 h were found to be 62.15% and 63.05% respectively. The data's obtained were compared respectively with that of E1 and C1. The results were almost similar and hence showed good reproducibility.
CONCLUSION
The formulation using Eudragit RL 100 and cellulose acetate showed a constant rate of release. Thus, prepared floating hollow microspheres of famotidine may prove to be potential candidates for a multiple-unit drug delivery device adaptable for any intragastric condition.
